In summary, our study depicts a novel mechanism through which PKM2 plays a critical role in the pathophysiology of AKI and demonstrates that targeting PKM2 may be a viable option for the reversal of podocyte damage and the progressive loss of nephrons. This evidence concerns the gene PKM and acute kidney injury.